[go: up one dir, main page]

BR0213994A - Derivados heterocìclicos de glicinamida e seus usos médicos - Google Patents

Derivados heterocìclicos de glicinamida e seus usos médicos

Info

Publication number
BR0213994A
BR0213994A BR0213994-4A BR0213994A BR0213994A BR 0213994 A BR0213994 A BR 0213994A BR 0213994 A BR0213994 A BR 0213994A BR 0213994 A BR0213994 A BR 0213994A
Authority
BR
Brazil
Prior art keywords
heterocyclic
medical uses
glycinamide derivatives
glycinamide
derivatives
Prior art date
Application number
BR0213994-4A
Other languages
English (en)
Inventor
Richard Leonard Elliott
Deirdre Mary Bernadette Hickey
Robert John Ife
Colin Andrew Leach
John Liddle
Ivan Leo Pinto
Steven James Stanway
Stephen Allan Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of BR0213994A publication Critical patent/BR0213994A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"DERIVADOS HETEROCìCLICOS DE GLICINAMIDA E SEUS USOS MéDICOS". Compostos da fórmula (I) são inibidores da enzima Lp-PLA~ 2~ e são utilizados em terapia, em particular para o tratamento de aterosclerose.
BR0213994-4A 2001-11-10 2002-11-08 Derivados heterocìclicos de glicinamida e seus usos médicos BR0213994A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0127141.0A GB0127141D0 (en) 2001-11-10 2001-11-10 Novel compounds
PCT/EP2002/012505 WO2003042179A1 (en) 2001-11-10 2002-11-08 Heterocyclic derivatives of glycinamide and their medical use

Publications (1)

Publication Number Publication Date
BR0213994A true BR0213994A (pt) 2004-08-31

Family

ID=9925627

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213994-4A BR0213994A (pt) 2001-11-10 2002-11-08 Derivados heterocìclicos de glicinamida e seus usos médicos

Country Status (19)

Country Link
US (1) US20050043335A1 (pt)
EP (1) EP1442020A1 (pt)
JP (1) JP2005511622A (pt)
KR (1) KR20050044366A (pt)
CN (1) CN1289483C (pt)
AU (1) AU2002351921B2 (pt)
BR (1) BR0213994A (pt)
CA (1) CA2468497A1 (pt)
CO (1) CO5580825A2 (pt)
GB (1) GB0127141D0 (pt)
HU (1) HUP0402244A2 (pt)
IL (1) IL161854A0 (pt)
MX (1) MXPA04004372A (pt)
NO (1) NO20042406L (pt)
NZ (1) NZ532520A (pt)
PL (1) PL369521A1 (pt)
RU (1) RU2004117603A (pt)
WO (1) WO2003042179A1 (pt)
ZA (1) ZA200403186B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1887000A4 (en) * 2005-05-27 2011-09-07 Shionogi & Co ARYLACETATE DERIVATIVES WITH ISOXAZO EASY
US7705005B2 (en) * 2006-10-13 2010-04-27 Glaxo Group Limited Bicyclic heteroaromatic compounds
KR101461659B1 (ko) 2007-05-11 2014-11-17 토마스 제퍼슨 유니버시티 신경변성 질환 및 장애의 치료 및 예방 방법
AU2008251467B2 (en) 2007-05-11 2014-07-31 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
KR101861883B1 (ko) 2010-12-06 2018-05-28 글락소 그룹 리미티드 Lp-PLA₂에 의해 매개되는 질환 또는 상태의 치료에 사용하기 위한 피리미디논 화합물
EP2651403B1 (en) 2010-12-17 2020-12-02 Glaxo Group Limited Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
CN103619831B (zh) 2011-06-27 2016-05-04 中国科学院上海药物研究所 唑类杂环化合物、其制备方法、药物组合物和用途
UY34216A (es) 2011-07-27 2013-02-28 Glaxo Group Ltd Nuevos compuestos que inhiben la actividad de la Lp-PLA2
CA2842965A1 (en) 2011-07-27 2013-01-31 Glaxo Group Limited 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1h)-one compounds use as lp-pla2 inhibitors
EP2760840B1 (en) * 2011-09-30 2015-08-12 Bristol-Myers Squibb Company Quinolinone carboxamide inhibitors of endothelial lipase
KR20150108897A (ko) 2013-01-25 2015-09-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 2,3-디히드로이미다졸[1,2-c]피리미딘-5(1h)-온계의 지단백질-연관 포스포리파제 a2 (lp-pla2) 억제제
AU2014210260B2 (en) 2013-01-25 2016-08-04 Glaxosmithkline Intellectual Property Development Limited Bicyclic pyrimidone compounds as inhibitors of Lp-PLA2
KR20150111356A (ko) 2013-01-25 2015-10-05 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 화합물
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
CN112778331B (zh) 2019-11-09 2022-07-05 上海赛默罗生物科技有限公司 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1263740B1 (en) * 2000-02-16 2006-07-19 SmithKline Beecham plc Pyrimidine-4-one derivative as ldl-pla2 inhibitor

Also Published As

Publication number Publication date
HUP0402244A2 (hu) 2005-02-28
US20050043335A1 (en) 2005-02-24
CN1608053A (zh) 2005-04-20
RU2004117603A (ru) 2005-04-20
MXPA04004372A (es) 2004-08-11
KR20050044366A (ko) 2005-05-12
AU2002351921B2 (en) 2007-01-25
IL161854A0 (en) 2005-11-20
CN1289483C (zh) 2006-12-13
GB0127141D0 (en) 2002-01-02
WO2003042179A1 (en) 2003-05-22
NO20042406L (no) 2004-06-09
JP2005511622A (ja) 2005-04-28
EP1442020A1 (en) 2004-08-04
NZ532520A (en) 2006-12-22
CO5580825A2 (es) 2005-11-30
CA2468497A1 (en) 2003-05-22
PL369521A1 (en) 2005-04-18
ZA200403186B (en) 2005-01-14

Similar Documents

Publication Publication Date Title
BR0010220A (pt) Compostos de pirimidinona
BR0213994A (pt) Derivados heterocìclicos de glicinamida e seus usos médicos
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
CY1112442T1 (el) Παραγωγα πυριδινονης για θεραπεια αθηροσκληρωσης
BR0011130A (pt) Inibidores de metaloproteases
NO992492L (no) Benzamidoaldehyder og deres anvendelse som cystein-protease-inhibitorer
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
NO20042161L (no) Inhibitorer av 11-beta-hydroksysteroid dehydrogenase type 1
BR9909994A (pt) Quinolinas usadas como inibidores de mrs e bactericidas
DE69432035D1 (de) Saccharinderivate als proteolytische Enzyminhibitoren
NO20050497L (no) Anvendelse av CETP inhibitorer og eventuelt HMG COA reduserbare inhibitorer og/eller antihypertensiva
DE60218458D1 (de) Isochinolinon derivate als parp inhibitoren
BRPI0410078A (pt) uso de efetuadores de ciclases de glutaminila e glutamato
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
MY132106A (en) New pyridazin-3(2h)-one derivatives
BRPI0416692A (pt) inibidores heterocìclicos de mek e métodos de emprego destes
DE69232929D1 (de) Saccharinderivate als proteolytische Enzyminhibitoren
TR200200883T2 (tr) 2-ikameli 1,1-bifenil-2-karbonamidler, imalat yöntemleri, ilaç olarak kullanılmaları
BR0109211A (pt) Compostos com atividade 5-ht1a úteis para o tratamento de distúrbios da retina externa
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
SE9802208D0 (sv) Novel compounds
BR0011778A (pt) Tienopirimidinas
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
BR0013781A (pt) Pirazolo [4,3-d]pirimidinas
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010.